Qingdao Haier Biomedical Co.,Ltd. (688139.SH) has released an announcement regarding a proposed share repurchase initiative.
The company intends to utilize its own funds to repurchase shares via a centralized bidding trading system, with all repurchased shares slated for capital reduction.
The total amount earmarked for the buyback is no less than 50 million yuan and no more than 100 million yuan.
The maximum price per share for the repurchase is set at 46 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments